Association between use of proton pump inhibitors and a Clostridium difficile-associated disease outbreak: Case-control study

Canadian Journal of Hospital Pharmacy

Volumn 63, Issue 1, 2010, Pages 31-37

  Linney, Stephanie ^a   Fernandes, Tania ^b   Einarson, Thomas ^c   Sengar, Anjana ^b,d   Walker, John H ^e,f   Mills, Allan ^b  

^a SUDBURY REGIONAL HOSPITAL   (Canada)

^b Trillium Health Centre Missassauga   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF COLORADO   (United States)

^e BROCK UNIVERSITY   (Canada)

^f PharmIdeas Research and Consulting Inc   (Canada)

Author keywords

Antibiotic; Clostridium difficile; Outbreak; Proton pump inhibitor; Risk factor

Indexed keywords

CEPHALOSPORIN; CLINDAMYCIN; PENICILLIN DERIVATIVE; PROTON PUMP INHIBITOR; QUINOLONE DERIVATIVE;

AGED; ARTICLE; CASE CONTROL STUDY; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DIABETES MELLITUS; ENTERIC FEEDING; ENTERITIS; EPIDEMIC; FEMALE; GASTROINTESTINAL SURGERY; HUMAN; MAJOR CLINICAL STUDY; MALE; NONHUMAN; RISK FACTOR;

EID: 84055214111     PISSN: 00084123     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Poutanen SM, Simor AE. Clostridium difficile-associated diarrhea in adults. CMAJ 2004;171(1):51-58. (Pubitemid 38925121)
2. Provincial Infectious Diseases Advisory Committee. Best practices document for the management of Clostridium difficile in all health care settings. Toronto (ON): Ministry of Health and Long Term Care; 2004 [revised 2007 Jun; cited 2007 Jun 4]. Available from: www.health.gov.on.ca/ english/providers/program/infectious/diseases/ic-cdiff.html
3. Gravel D, Miller M, Simor A, Taylor G, Gardam M, McGeer A, et al. Canadian Nosocomial Infection Surveillance Program. Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis 2009;48(5):568-576.
4. LaMont JT. Pathophysiology and epidemiology of Clostridium difficile infection. Waltham (MA): UpToDate Online; 2007 Jan 28 [cited 2007 Aug 10]. Available from: www.utdol.com. Content password-protected.
5. Owens RC Jr, Donskey CJ, Gaynes RP, Loo VG, Muto CA. Antimicrobialassociated risk factors for Clostridium difficile infection. Clin Infect Dis 2008;46 Suppl 1:S19-S31. (Pubitemid 351323662)
6. Gerding DN, Johnson S, Peterson LR, Mulligan ME, Silva J Jr. Clostridium difficile associated diarrhea and colitis. Infect Control Hosp Epidemiol 1995;16(8):459-74.
7. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998;40(1):1-15. (Pubitemid 28438966)
8. Blot E, Escande MC, Besson D, Barbut F, Granpeix C, Asselain B, et al. Outbreak of Clostridium difficile-related diarrhoea in an adult oncology unit: risk factors and microbiological characteristics. J Hosp Infect 2003;53(3):187-192. (Pubitemid 38002053)
9. Williams C, McColl KEL. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006;23(1):3-10. (Pubitemid 43381161)
10. Howden CW, Hunt RH. Relationship between gastric secretion and infection. Gut 1987;28(1):96-107. (Pubitemid 17231555)
11. Thorens J, Froehlich F, Schwizer W, Saraga E, Bille J, Gyr K, et al. Bacterial overgrowth during treatment with omeprazole compared with cimetidine: a prospective randomised double blind study. Gut 1996;39(1): 54-9. (Pubitemid 26239105)
12. Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005;294(23):2989-2995. (Pubitemid 41817660)
13. Dial S, Alradasi K, Manoukian C, Huang A, Menzies D. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ 2004;171(1):33-38. (Pubitemid 38925116)
14. Dial S, Delaney JAC, Schneider V, Suissa S. Proton pump inhibitor use and risk of community-acquired Clostridium difficile-associated disease defined by prescription for oral vancomycin therapy. CMAJ 2006; 175(7):745-748. (Pubitemid 44520987)
15. Cunningham R, Dale B, Undy B, Gaunt N. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003; 54(3):243-245. (Pubitemid 38002001)
16. Yearsley KA, Gilby LJ, Ramadas AV, Kubiak EM, Fone DL, Allison MC. Proton pump inhibitor therapy is a risk factor for Clostridium difficileassociated diarrhoea. Aliment Pharmacol Ther 2006;24(4):613-619. (Pubitemid 44127842)
17. Lowe DO, Mamdani MM, Kopp A, Low DE, Juurlink DN. Proton pump inhibitors and hospitalization for Clostridium difficile-associated disease: a population-based study. Clin Infect Dis 2006;43(10):1272-1276. (Pubitemid 44706452)
18. Shah S, Lewis A, Leopold D, Dunstan F, Woodhouse K. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM 2000;93(3):175-81. (Pubitemid 30128705)
19. Pépin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, et al. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41(9):1254-1260. (Pubitemid 41532667)
20. Leonard J, Marshall JK, Moayyedi P. Systemtic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007; 102(9):2047-2056. (Pubitemid 47301504)
21. Pantoprazole Drugdex evaluation. In: Micromedex Healthcare Series. Thomson Healthcare; 2007 [cited 2007 Sep 9]. Available from: www.thomsonhc.com. Content password-protected.
22. Oral acid suppression comparison chart. In: RxFiles pocketbook. 6th ed. Saskatoon (SK): Saskatoon Health Region; 2007. p. 35. Also available from: www.rxfiles.ca. Content password-protected.
23. Stokes ME, Davis CS, Koch GG. Categorical data analysis using the SAS®system. 2nd ed. Cary (NC): SAS Institute Inc; 2000.
24. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York (NY): John Wiley & Sons; 2000.